Navigation Links
ASINEX and CDD Team up for Open Access Data for the Scientific Community
Date:5/20/2008

SAN FRANCISCO, May 20 /PRNewswire/ -- ASINEX and Collaborative Drug Discovery (CDD), Inc. have formed a collaboration showcasing ASINEX high value compound libraries via the CDD Community Database. The first high value set offered is the ASINEX Lead Generation Library with additional libraries to follow. ASINEX and CDD have created special screening sets tailored to the specific needs of (and now available via the CDD Database to any) academic researchers. The combined information is being made available to the general public via CDD for the first time at https://www.collaborativedrug.com/register.

Mark Parisi, the Executive Director at ASINEX stated, "CDD has an impressive group of collaborators and ASINEX looks forward to helping this group with its early drug discovery efforts."

Barry Bunin, the President of CDD commented, "This begins a qualitatively different phase of the CDD platform by bringing quality industry products and services to the growing community -- and vice-versa."

Every compound uploaded from ASINEX can be viewed within the context of your own private, secure data for scaffold jumping via substructure or Tanimoto similarity search within the merged data for lead identification and optimization. The main premise is for new screens, fewer compounds of higher quality are often required. This means more different scaffolds with fewer compounds per scaffold for greater coverage of novel chemical space (novel IP) without creating compounds so lipophilic that they violate the more traditional rule of 5 (which ASINEX has further refined to a rule of 4.5).

CDD has included other complementary data sets including a list of FDA/Ophran approved drugs courtesy of Dr. Christopher Lipinski, a set of known aggregators likely to cause false positives courtesy of Dr. Brian Shoichet, a set of toxicity profiles on known compounds courtesy of Dr. Sean Ekins, and numerous sets of Malaria and Tuberculosis SAR data which can now be compared with commercial compounds from ASINEX in personal, secure private groups. From a purely economical perspective, a strong argument can be made that it makes sense to screen fewer, high-quality compounds resulting in higher quality leads at lower overall cost. ASINEX has a strong reputation for quality, especially in Europe. This collaboration with CDD will help bring awareness of these compounds to academic laboratories and smaller startup companies who require a more cost-effective mechanism for collaborative drug discovery.

About ASINEX: With more than a fourteen year history, ASINEX is a world leader in supplying compound libraries, focused libraries, custom libraries, and building blocks for early drug discovery. ASINEX also has a growing list of partners who have decided to utilize its computational, custom synthesis, and biology services for lead optimization projects. The company has a total of 151 chemists (54 Ph.D.), 9 computational chemists (7 Ph.D.) and 38 biologists / biochemists (24 Ph.D.). For more info please contact:

ASINEX Corporation

Mark Parisi

Executive Director

Toll Free Tel.: 1-877-ASINEX1 (1-877-274-6391)

Email: MParisi@asinex.com

About CDD: CDD is the world's first platform for selectively sharing collaborative drug discovery data. Scientists working with the CDD community platform can pool their research in order to more effectively develop new drug candidates for commercial and humanitarian markets. Conceived in 2003, and formally launched in 2004, Collaborative Drug Discovery (CDD) has been serving the collaborative data needs of researchers for years. The CDD global community includes hundreds of scientists from leading research foundations, academia and industry. A subset of the data is available openly to the public at no cost. For more information, please visit http://www.collaborativedrug.com or contact:

Collaborative Drug Discovery, Inc. (CDD, Inc.)

Barry Bunin, PhD

President

info@collaborativedrug.com

Tel: (650) 204-3084


'/>"/>
SOURCE Collaborative Drug Discovery, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
3. Open access to health research publications
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. Care reforms raise concerns over patient access to GP services
6. Access Innovations Provides Support Services for Agis Network
7. RAND researchers offer options to improve immigrant health care quality, access
8. Uninsured community health center patients often have difficulty accessing specialty services
9. Hispanics hypertension better controlled with equal access to care
10. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
(Date:3/28/2017)... GA (PRWEB) , ... March 28, 2017 , ... With ... to Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville ... location since 2016. The new office allows opportunity for transition of Patten Seed operations ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing immunogene ... Chief Operating Officer, is scheduled to present a corporate overview at ... Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 ... ... Future Leaders in Biotech Industry – Friday, April 7, 2017 at ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
Breaking Medicine Technology: